title: Immunization with the Candida albicans membrane fraction and in combination with fluconazole protects against systemic fungal infections.
abstract: We studied the immunogenicity of a membrane fraction prepared from Candida albicans cells called C. albicans membrane antigen (CMA). The present study revealed that CMA immunization has antifungal activity in mouse models of systemic fungal infection. Immunization of mice by subcutaneous injections of CMA with incomplete Freund adjuvant induced resistance to infections caused not only by C. albicans but also by Aspergillus fumigatus. The level of resistance to candidiasis was as high as that induced by whole-cell immunization. The acquired resistance to candidiasis in the mice immunized with CMA was not diminished by immunosuppressive treatment with cyclophosphamide. The level of resistance to fungal infections was superior to that given by fluconazole (FLC) treatment alone and highly enhanced by the combination with FLC. When CD4(+) cells in CMA-immunized mice were depleted by a monoclonal antibody, the antifungal activity induced by the combination of CMA and FLC was significantly reduced. These results indicate that immunization with CMA is useful for preventing systemic fungal infections and in combination with FLC for increasing resistance after infection.
authors.affiliation: Biotechnology Research Laboratories, Takara Shuzo Co., Ltd., 3-4-1 Seta, Otsu, Shiga 520-2193, Japan. mizutanis@takara.co.jp
authors.forename: S
authors.initials: S
authors.lastname: Mizutani
authors.forename: M
authors.initials: M
authors.lastname: Endo
authors.forename: T
authors.initials: T
authors.lastname: Ino-Ue
authors.forename: M
authors.initials: M
authors.lastname: Kurasawa
authors.forename: Y
authors.initials: Y
authors.lastname: Uno
authors.forename: H
authors.initials: H
authors.lastname: Saito
authors.forename: I
authors.initials: I
authors.lastname: Kato
authors.forename: K
authors.initials: K
authors.lastname: Takesako
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D000935:Antifungal Agents / Q000627:therapeutic use*; D000946:Antigens, Fungal / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002176:Candida albicans / Q000276:immunology*; D002177:Candidiasis / Q000276:immunology / Q000517:prevention & control*; D002462:Cell Membrane / Q000276:immunology; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000494:pharmacology; D004195:Disease Models, Animal; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use*; D016469:Fungemia / Q000276:immunology / Q000517:prevention & control*; D007114:Immunization; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007371:Interferon-gamma / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL
chemical_list: D000911:Antibodies, Monoclonal; D000935:Antifungal Agents; D000946:Antigens, Fungal; D007166:Immunosuppressive Agents; D007371:Interferon-gamma; D003520:Cyclophosphamide; D015725:Fluconazole